Arcadia Biosciences’ GoodWheat™ Supply Chain Is Progressing in Two Hemispheres

Winter planting expands acres and builds supply for commercial
launch —

DAVIS, Calif.–(BUSINESS WIRE)–Demonstrating its commitment to advancing its GoodWheat™ portfolio of
novel, non-GM wheat ingredients with unique health benefits to
commercialization, Arcadia
Biosciences, Inc.
(Nasdaq: RKDA), an agricultural food ingredient
company, today announced additional progress in the development of its
supply chain, led by Grant Aldridge, the company’s new Head of
Commercial Development.

Since mid-2018, Arcadia has significantly expanded its grower base for
unique GoodWheat varieties to provide adequate supply for its consumer
and animal feed customers. To preserve the unique characteristics of
GoodWheat, the company has developed a robust identity preservation
system that ensures the wheat’s unique quality is maintained throughout
the supply chain, from seed to food company. In addition, the company
just completed counter-season planting of GoodWheat, which will increase
seed inventory available for Arcadia’s grower partners. In 2019, the
company plans to expand acres in the southern hemisphere which will
expedite supply through a two-hemisphere production cycle and will
increase access to key markets for the commercial adoption of GoodWheat.

All these activities are being driven by Aldridge, a crop production
agriculture expert who brings more than 25 years of experience in
agribusiness to Arcadia. Aldridge has served leadership roles in several
major agriculture and biotechnology companies, executing new market
models for high-value traits in corn, soybeans, melons and novel
industrial crops. He has enjoyed a track record of success in every
aspect of commercialization, from research and product development to
commercial operations like sales, marketing and crop production
management. Aldridge has a master’s degree in plant genetics and
breeding from Purdue University.

“These supply chain advancements demonstrate our commitment to bringing
our GoodWheat portfolio to market, enabling consumers to improve
nutrition by eating foods they love,” said Raj Ketkar, president and CEO
of Arcadia. “Grant is an excellent addition to our team, and he adds the
level of expertise and proven experience that will help us successfully
launch GoodWheat.”

“What has impressed me about Arcadia is the progress being made driving
tangible innovation in wheat – a crop that has seen limited innovation
over the past 75 years,” said Aldridge. “With the GoodWheat product
portfolio, we will enhance value throughout the supply chain, allowing
growers to capture more value on the farm, consumer packaged goods
companies to differentiate their brands in the marketplace, and
consumers to get the nutrients they need by eating foods they enjoy.”

Arcadia’s GoodWheat platform is a portfolio of novel non-GM wheat
varieties including high fiber resistant starch, reduced gluten and
others. These varieties have been specially bred for unique value using
Arcadia’s non-GM TILLING platform and can be delivered as organic or
conventional wheat. GoodWheat was developed to add value to the entire
wheat supply chain, from seed to table, by enabling a wider range of
healthy choices to meet evolving consumer demands. First sales of
GoodWheat are expected in the next 12 months.

About Arcadia Biosciences, Inc.

Arcadia Biosciences, Inc. (Nasdaq: RKDA) develops and markets high-value
food ingredients and nutritional oils that help meet consumer demand for
a healthier diet. Arcadia’s GoodWheat™ branded ingredients deliver
health benefits to consumers and enable consumer packaged goods
companies to differentiate their brands in the marketplace. The
company’s agricultural traits are being developed to enable farmers
around the world to be more productive and minimize the impact of
agriculture on the environment. For more information, visit

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: Arcadia’s and
its partners’ and affiliates’ ability to develop commercial products
incorporating their traits, and complete the regulatory review process
for such products; Arcadia’s compliance with laws and regulations that
impact Arcadia’s business, and changes to such laws and regulations;
Arcadia’s future capital requirements and ability to satisfy its capital
needs; Arcadia’s ability to develop, enforce and defend its intellectual
property rights; and the other risks set forth in Arcadia’s filings with
the Securities and Exchange Commission from time to time, including the
risks set forth in Arcadia’s Annual Report on Form 10-K for the year
ended December 31, 2017 and other filings. These forward-looking
statements speak only as of the date hereof, and Arcadia Biosciences,
Inc. disclaims any obligation to update these forward-looking statements.


Arcadia Biosciences
Jeff Bergau

error: Content is protected !!